A glucose-blue light AND gate-controlled chemi-optogenetic cell-implanted therapy for treating type-1 diabetes in mice

Exogenous insulin therapy is the mainstay treatment for Type-1 diabetes (T1D) caused by insulin deficiency. A fine-tuned insulin supply system is important to maintain the glucose homeostasis. In this study, we present a designed cell system that produces insulin under an AND gate control, which is...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chi-Yu, Wu, Ting, Zhao, Xing-Jun, Yu, Cheng-Ping, Wang, Zi-Xue, Zhou, Xiao-Fang, Li, Shan-Ni, Li, Jia-Da
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Bioengineering and Biotechnology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954140/
https://www.ncbi.nlm.nih.gov/pubmed/36845170
http://dx.doi.org/10.3389/fbioe.2023.1052607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954140/
https://www.ncbi.nlm.nih.gov/pubmed/36845170
http://dx.doi.org/10.3389/fbioe.2023.1052607

Ejemplares similares